VANCOUVER, June 11 /PRNewswire-FirstCall/ - Biotech Holdings reports that it has launched a website, www.sucanonhealth.com, for internet sales of Sucanon, a Type II diabetes drug.
Sucanon, which is broadly classed as an insulin-sensitizing drug, has been shown to be an effective and very safe treatment for Type II Diabetes, without the side-effects that are associated with several competing Type II Diabetes medications including the glitazone medications which are now the subject of a "black box" warning by the U.S. FDA. (see New York Times, June 7, 2007, page 1 and http://www.msnbc.msn.com/id/19090626/).
Sucanon has received regulatory approval in Mexico, is widely sold there and has received the support of the Mexican Diabetes Federation. In addition, an agreement has recently been signed for expansion of retail distribution to four other Latin American markets as outlined in a news release of May 30, 2007 on yahoo http://biz.yahoo.com/prnews/070530/to380.html?.v=20, and on Biotech Holdings' website, www.biotechltd.com.
The website www.sucanonhealth.com makes Sucanon available to Type II diabetics, without prescription, in countries worldwide including the United States and Canada which do not require regulatory approval for drugs that are imported only for personal use and are not re-sold.
To learn more about or order Sucanon, see www.sucanonhealth.com.
This release has been approved by the Board of Directors of Biotech Holdings.
The TSX Venture Exchange does not accept responsibility for the adequacy
or accuracy of this release.
Robert B. Rieveley, Pres.
On behalf of the Board of Directors
Any statements made in this release that are not based on historical fact are forward-looking statements. Any forward-looking statements made in this release represent management's best judgement as to what may occur in the future. However, actual outcome and results are not guaranteed and are subject to certain risks, uncertainties and assumptions and may differ materially from what is expressed. There is no assurance that internet sales of Sucanon will be material.
If you wish to be removed from Biotech Holdings' email news distribution list, please reply by email, putting "remove" in the subject line.
CONTACT: contact Austin Rand at Biotech Holdings, 1-888-216-1111 (toll-free) 8 a.m. to 4 p.m. Pacific time; For background information on Biotech Holdings, or to receive news updates, see www.biotechltd.com; Directors of the company can be reached by calling (604) 295-1119
Biotech Holdings Ltd.